Gast ::
| Hauptseite > Publikationsdatenbank > Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum > print |
| Hauptseite > Publikationsdatenbank > Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum > print |
| 001 | 1027025 | ||
| 005 | 20250204113901.0 | ||
| 024 | 7 | _ | |a 10.1016/j.msard.2024.105664 |2 doi |
| 024 | 7 | _ | |a 2211-0348 |2 ISSN |
| 024 | 7 | _ | |a 2211-0356 |2 ISSN |
| 024 | 7 | _ | |a 10.34734/FZJ-2024-03591 |2 datacite_doi |
| 024 | 7 | _ | |a 38735204 |2 pmid |
| 024 | 7 | _ | |a WOS:001243115500001 |2 WOS |
| 037 | _ | _ | |a FZJ-2024-03591 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Schweitzer, Finja |0 0000-0003-0707-0485 |b 0 |
| 245 | _ | _ | |a Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2024 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1717995927_11605 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Background: Natalizumab is an effective treatment for relapsing multiple sclerosis (MS). During therapy, individualsare at increased risk of developing progressive multifocal leukoencephalopathy (PML). So far, therelevant reservoir for PML-type JC polyomavirus (JCV) remains elusive. We here tested if the detection of JCVDNAin stool of persons with MS treated with natalizumab could be a future tool for PML risk assessment.Methods: The presence of JCV-DNA in stool, urine, and whole blood of MS patients treated with natalizumab andknown serum anti-JCV antibodies index values (IV) was studied. Different DNA extraction methods, real-time(RT) and droplet digital (dd) PCR techniques were compared. JCV isolates were screened for PML-associatedvariants by sequencing.Results: Thirty MS patients treated with natalizumab were screened. For 21 patients, blood, stool, and urinesamples were available. These patients were stratified according to their serum anti-JCV antibody IV (high (>1.5,n = 12); medium (1.5–0.9, n = 2); low (<0.9, n = 1); negative (n = 6)). JCV-DNA could not be detected in thewhole blood or stool samples. Four urine samples had measurable JCV-DNA, ranging from 1.71×104–1.07×108international units (IU)/mL detected by RT-PCR, corresponding to 4.62×104–9.85×106 copies/mL measured byddPCR. All JCV variants were wild-type and derived from patients with high antibody IV.Conclusion: Stool-specific DNA extraction methods provided the highest quality of DNA, while the sensitivity ofddPCR and RT- PCR was comparable. Our findings do not support assessing stool samples for PML risk stratificationin persons with MS. Further studies are needed to explore where PML-associated viral variants arise. |
| 536 | _ | _ | |a 5251 - Multilevel Brain Organization and Variability (POF4-525) |0 G:(DE-HGF)POF4-5251 |c POF4-525 |f POF IV |x 0 |
| 536 | _ | _ | |a DFG project 501362249 - Progressive multifokale Leukenzephalopathie: Biomarker für eine frühzeitige Diagnose, für die Risikovorhersage unter Immuntherapien sowie für ein Ansprechen auf eine zielgerichtete Therapie (501362249) |0 G:(GEPRIS)501362249 |c 501362249 |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Ladwig, Anne |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Opala, Sarah |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Laurent, Sarah |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Schroeter, Michael |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Goelz, Susan |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Fink, Gereon R. |0 P:(DE-Juel1)131720 |b 6 |u fzj |
| 700 | 1 | _ | |a Wieland, Ulrike |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Silling, Steffi |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Warnke, Clemens |0 0000-0002-3510-9255 |b 9 |e Corresponding author |
| 773 | _ | _ | |a 10.1016/j.msard.2024.105664 |g Vol. 87, p. 105664 - |0 PERI:(DE-600)2645330-7 |p 105664 - |t Multiple Sclerosis and Related Disorders |v 87 |y 2024 |x 2211-0348 |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/1027025/files/PDF.pdf |
| 856 | 4 | _ | |y OpenAccess |x icon |u https://juser.fz-juelich.de/record/1027025/files/PDF.gif?subformat=icon |
| 856 | 4 | _ | |y OpenAccess |x icon-1440 |u https://juser.fz-juelich.de/record/1027025/files/PDF.jpg?subformat=icon-1440 |
| 856 | 4 | _ | |y OpenAccess |x icon-180 |u https://juser.fz-juelich.de/record/1027025/files/PDF.jpg?subformat=icon-180 |
| 856 | 4 | _ | |y OpenAccess |x icon-640 |u https://juser.fz-juelich.de/record/1027025/files/PDF.jpg?subformat=icon-640 |
| 909 | C | O | |o oai:juser.fz-juelich.de:1027025 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)131720 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5251 |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-26 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-26 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MULT SCLER RELAT DIS : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-06 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2025-01-06 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|